anti-CD11a MAb (Geneva University)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD11a MAb (Geneva University)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionComplement system proteins inhibitorsLeukocyte adhesion glycoprotein LFA-1 alpha antagonists
TargetsLeukocyte adhesion glycoprotein LFA-1 alphaComplement system proteins
Therapy Area/IndicationsRespiratory Distress Syndrome, AdultPulmonary FibrosisShock, Septic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Geneva
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Geneva
Active IndicationsN/A
Inactive IndicationsRespiratory Distress Syndrome, AdultPulmonary FibrosisShock, Septic

Other Information

ATC CodeN/A
Related LinksN/A